Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-01-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2010-08-299396PMID 21030558PMCID PMC3035073
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.

  2011cited by this paper
• The role of maintenance therapy in the treatment of multiple myeloma.

  2010cited by this paper
• New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.

  2010cited by this paper
• A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

  2010cited by this paper
• Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count

  2010cited by this paper
• Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

  2010cited by this paper
• Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B‐cell lymphoma

  2009cited by this paper
• Immune therapy for cancer.

  2009cited by this paper
• Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells

  2009cited by this paper
• The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma

  2009cited by this paper
• Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.

  2008cited by this paper
• The Immunomodulatory Role of Lenalidomide on Prevnar® Responses in Patients with Relapsed Multiple Myeloma: A Comprehensive Analysis of the Immune Response

  2008cited by this paper
• Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study

  2008cited by this paper
• Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance.

  2007cited by this paper
• Significant impact of survivin on myeloma cell growth

  2007cited by this paper
• CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma

  2007cited by this paper
• Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma

  2006cited by this paper
• Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

  2006cited by this paper
• Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

  2006cited by this paper
• Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

  2006cited by this paper
• Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients

  2005cited by this paper
• Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer

  2005cited by this paper
• Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple

  2005cited by this paper
• The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

  2005cited by this paper
• The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma.

  2004cited by this paper
• Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy

  2004cited by this paper
• GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL.

  2004cited by this paper
• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  2003cited by this paper
• Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival.

  2003cited by this paper
• HER-2/neu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy1

  2002cited by this paper
• Small‐Sample Inference for Incomplete Longitudinal Data with Truncation and Censoring in Tumor Xenograft Models

  2002cited by this paper
• T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.

  2001cited by this paper
• Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.

  2001cited by this paper
• Humoral immunity to viral and bacterial antigens in lymphoma patients 4–10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines

  2001cited by this paper
• Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.

  2001cited by this paper
• Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa.

  2001cited by this paper
• p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes

  2000cited by this paper
• Telomerase activity in plasma cell dyscrasias

  2000cited by this paper
• Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.

  1999cited by this paper
• CD3- and CD28-dependent induction of PDE7 required for T cell activation.

  1999cited by this paper
• Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections

  1999cited by this paper
• The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.

  1999cited by this paper
• Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation.

  1998cited by this paper
• Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

  1997cited by this paper
• Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.

  1997cited by this paper
• Graft-versus-myeloma effect: proof of principle.

  1996cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996cited by this paper
• CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro.

  1995cited by this paper
• Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes

  1994cited by this paper
• Immune therapy of cancer.

  1988cited by this paper

• The role of telomere and telomerase in cancer and novel therapeutic target: narrative review

  2025cites this paper
• Breaking Barriers in CRC Immunotherapy: Cutting-Edge Advances in Personalized Peptide Vaccine Development.

  2025cites this paper
• Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy

  2025cites this paper
• Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

  2025cites this paper
• Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma.

  2024cites this paper
• Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics

  2024cites this paper
• Advances and challenges in anti-cancer vaccines for multiple myeloma

  2024cites this paper
• Personalized Medicine's Coming of Age: One Drug, One Patient.

  2023cites this paper
• Highlights into historical and current immune interventions for cancer.

  2023cites this paper
• Evaluation of in vitro immunostimulatory and cytotoxic effects of recombinant survivin protein in combination with doxorubicin and breast cancer antigen-loaded polycaprolactone nanoparticles

  2023cites this paper
• Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401

  2023cites this paper
• Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges

  2022cites this paper
• Potential association factors for developing effective peptide-based cancer vaccines

  2022cites this paper
• BSA‐AIE Nanoparticles with Boosted ROS Generation for Immunogenic Cell Death Immunotherapy of Multiple Myeloma

  2022cites this paper
• It takes T to tango: immunotherapy in MM.

  2022cites this paper
• Therapeutic cancer vaccine therapy for acute myeloid leukemia.

  2021cites this paper
• Post-Transplant Maintenance Treatment Options in Multiple Myeloma

  2021cites this paper
• Critical Period After Stroke Study (CPASS): A phase II clinical trial testing an optimal time for motor recovery after stroke in humans

  2021cites this paper
• Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy

  2021cites this paper
• Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens

  2021cites this paper
• A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients.

  2021cites this paper
• Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy

  2021cites this paper
• An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia

  2020cites this paper
• Why Immunotherapy Fails in Multiple Myeloma

  2020cites this paper
• Cancer Immunotherapy Confers a Global Benefit

  2020cites this paper
• Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics

  2020cites this paper
• Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy

  2020cites this paper
• Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse

  2020cites this paper
• Anti-Cancer Immunotherapies Targeting Telomerase

  2020cites this paper
• Telomerase-based cancer therapeutics: a review on their clinical trials.

  2020cites this paper
• Development of tumour peptide vaccines: From universalization to personalization

  2020cites this paper
• Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities

  2020cites this paper
• Immunotherapeutic Strategies for Multiple Myeloma

  2020cites this paper
• Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR

  2019cites this paper
• In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma

  2019cites this paper
• Myeloma: next generation immunotherapy.

  2019cites this paper
• HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells

  2019cites this paper
• T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma.

  2019cites this paper
• Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma

  2019cites this paper
• Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

  2019cites this paper
• Adoptive Immunotherapy and Cellular Therapy

  2019cites this paper
• How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma

  2019cites this paper
• Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.

  2018cites this paper
• CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.

  2018cites this paper
• Prevention and treatment of relapse after stem cell transplantation with immunotherapy

  2018cites this paper
• Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’

  2018cites this paper
• Anti-CD 19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

  2018cites this paper
• Immune T cells can transfer and boost anti-breast cancer immunity

  2018cites this paper
• Anti-cancer vaccine therapy for hematologic malignancies: An evolving era.

  2018cites this paper
• T Cell Receptors-Gene-Modified T Cells for Cancer: Methods, Data, and Challenges

  2018cites this paper
• Cellular immunotherapy as a therapeutic approach in multiple myeloma

  2018cites this paper
• Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

  2018cites this paper
• Engineered T Cells for glioblastoma therapy

  2018cites this paper
• Adoptive cell therapy in multiple Myeloma

  2017cites this paper
• Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy

  2017cites this paper
• Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

  2017cites this paper
• Hematologic Malignancies: Plasma Cell Disorders.

  2017cites this paper
• A second chance for telomerase reverse transcriptase in anticancer immunotherapy

  2017cites this paper
• Recent advances in T‐cell immunotherapy for haematological malignancies

  2017cites this paper
• In vitro generation of cytotoxic T cells with potential for adoptive tumour immunotherapy

  2017cites this paper
• Current treatment options of T cell-associated immunotherapy in multiple myeloma

  2017cites this paper
• Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia

  2017cites this paper
• Survival analysis with functional covariates for partial follow-up studies

  2016cites this paper
• Timing Is Everything: Combining Post-Transplantation Adoptive Cell Therapy and Tumor Vaccines.

  2016cites this paper
• Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma

  2016cites this paper
• 69. Adoptive T-cell Therapy for Malignancy in the Setting of Hematopoietic Cell Transplantation

  2016cites this paper
• Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.

  2016cites this paper
• Cellular and vaccine immunotherapy for multiple myeloma.

  2016cites this paper
• Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning

  2016cites this paper
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

  2016cites this paper
• Telomere and Telomerase Therapeutics in Cancer

  2016cites this paper
• Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

  2016cites this paper
• Stem Cell Antigens in Cancer

  2016cites this paper
• Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.

  2016cites this paper
• SELF-AMPLIFYING RNA VECTORS ENCODING SURVIVIN AS ANTI-TUMORAL VACCINE CANDIDATES Relatore: Prof. Diego Maria Michele FORNASARI Correlatore: Prof. Antonio SICCARDI Coordinatore del Dottorato: Prof. Massimo LOCATI

  2016cites this paper
• Recent advances in understanding multiple myeloma

  2016cites this paper
• Open Peer Review

  2016cites this paper
• Immunopharmacology

  2016cites this paper
• Therapeutic Targeting of Telomerase

  2016cites this paper
• Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.

  2016cites this paper
• The T Cell in Myeloma.

  2016cites this paper
• Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination

  2016cites this paper
• Immunopharmacologic Approaches to Treat Cancer

  2016cites this paper
• Inflammation and Cancer

  2016cites this paper
• EMPLOYING T CELLS FOR ANTIGEN PRESENTATION: ROLE OF NY-ESO-1+ T-APC VACCINE IN MULTIPLE MYELOMA

  2016cites this paper
• Clinical perspectives in cancer vaccines for hematological diseases

  2015cites this paper
• Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies

  2015cites this paper
• The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent

  2015cites this paper
• Antigen-specific T cell therapies for cancer.

  2015cites this paper
• Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma

  2015cites this paper
• Survivin-specific T cell receptor targets tumor but not T cells.

  2015cites this paper
• NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

  2015cites this paper
• A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

  2015cites this paper
• The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.

  2015cites this paper
• T cell‐based targeted immunotherapies for patients with multiple myeloma

  2015cites this paper
• Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation

  2015cites this paper
• Immune therapy in multiple myeloma.

  2015cites this paper
• Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy

  2015cites this paper
• Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma

  2015cites this paper
• Immunotherapy for multiple myeloma: Current status and future directions.

  2015cites this paper